Psyence Biomedical Ltd. is a holding company, which engages in the development and commercialization of pharmaceutical products in neurology. The company is headquartered in Toronto, Ontario and currently employs 12 full-time employees. The company went IPO on 2021-12-10. The firm is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. The company is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.
Follow-Up Questions
Psyence Biomedical Ltd (PBM) 的本益比是多少？
Psyence Biomedical Ltd 的本益比是 2.6223
Psyence Biomedical Ltd 的 CEO 是誰？
Mr. Marc Balkin 是 Psyence Biomedical Ltd 的 Chief Executive Officer，自 2021 加入公司。
PBM 股票的價格表現如何？
PBM 的當前價格為 $5.15，在上個交易日 decreased 了 2.73%。
Psyence Biomedical Ltd 的主要業務主題或行業是什麼？
Psyence Biomedical Ltd 屬於 Biotechnology 行業，該板塊是 Health Care
